Published • loading... • Updated
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
The plant will boost output of Foundayo and other medicines as Lilly says the pill now accounts for one in three new oral weight-loss starts.
- On Monday, Eli Lilly CEO Dave Ricks broke ground on a $6.5 billion manufacturing facility at Generation Park in Houston, Texas, expected to be operational by 2030.
- Ricks told CNBC that one-third of new GLP-1 pill patients are taking Foundayo, driving Lilly's production ramp to compete against rival Novo in the obesity-treatment market.
- Since 2020, Lilly has committed more than $50 billion to expand its manufacturing network, positioning itself to meet growing demand for obesity and diabetes treatments.
- Medicare's landmark obesity drug coverage, which began in July, is expected to expand access to Foundayo and Zepbound; Foundayo booked $98 million in second-quarter sales.
- Lilly committed an additional $27 billion in February 2025 to build four new facilities, including the Houston site, partly to build goodwill with President Donald Trump.
Insights by Ground AI
12 Articles
12 Articles
Coverage Details
Total News Sources12
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
